<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01783951</url>
  </required_header>
  <id_info>
    <org_study_id>S1+DC CIK- G</org_study_id>
    <nct_id>NCT01783951</nct_id>
  </id_info>
  <brief_title>Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer</brief_title>
  <official_title>Autologous Dendritic Cell-cytokine Induced Killer Cell Immunotherapy Combined With S-1 Based Chemotherapy in Patients With Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Geneplus-Beijing Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the antitumor effect and safety of clinical
      effectiveness dendritic cell activated Cytokine induced killer treatment (DC-CIK) plus S-1
      based chemotherapy for advanced gastric cancer.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival（PFS）</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Every 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Every 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>6 weeks</time_frame>
    <description>Evaluation of quality of life will be performed every 2 cycles (6 weeks) from baseline to the end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>DC-CIK plus S-1 based chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be receive S-1 based chemotherapy, including S-1 plus cisplatin or S-1 alone. Meanwhile those patients will receive DC-CIK cell therapy at days 15, 17 and 19 per cycle and received cycles of treatment once every 21 days.Treatment was continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S-1 based chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be receive S-1 based chemotherapy, including S-1 plus cisplatin or S-1 alone.Cycles were repeated every 21 days. Treatment was continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DC-CIK</intervention_name>
    <description>Patients will be receive DC-CIK cell therapy at days 15, 17 and 19 per cycle and received cycles of treatment once every 21 days.</description>
    <arm_group_label>DC-CIK plus S-1 based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>The dose of S-1 is determined according to the body surface area as follows: &lt;1.25 m2, 40 mg; 1.25 to &lt;1.5 m2, 50 mg; and ≥1.5 m2, 60 mg, given twice daily after meals for 14 days followed by 7 days rest.</description>
    <arm_group_label>DC-CIK plus S-1 based chemotherapy</arm_group_label>
    <arm_group_label>S-1 based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin is administered at 75 mg/m2 intravenously over 1 to 3 hours every 21 days.</description>
    <arm_group_label>DC-CIK plus S-1 based chemotherapy</arm_group_label>
    <arm_group_label>S-1 based chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically/cytologically confirmed recurrent or metastatic gastric or
             esophagogastric junctional adenocarcinoma

          -  Between 18 and 80 years old

          -  Capable of oral intake

          -  Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
             criteria

          -  Karnofsky Performance Status (KPS) ≥ 70%

          -  Normal functions of heart, lung and bone marrow

          -  Adequate hematological profile： Hemoglobin ≥ 9.0 g/dL Absolute granulocyte count ≥
             1,500/mm3 Platelet count ≥ 100,000/mm3

          -  Adequate hepatic function Total bilirubin level≤ 3.0 times the upper limit of normal
             (ULN) Transaminases AST (SGOT) and ALT (SGPT) ≤ 2.5 times ULN

          -  Adequate renal function(normal serum creatinine level)

          -  A life expectancy≥ 2 months

          -  Informed consent signed

        Exclusion Criteria:

          -  Current enrollment in another clinical study with an investigational agent. Patients
             participating in surveys or observational studies are eligible to participate in this
             study

          -  Any radiotherapy or surgery within the previous 4 weeks

          -  Symptomatic brain metastasis not controlled by corticosteroids

          -  Bone marrow metastasis

          -  Active infection

          -  Serious complications

          -  Receiving a concomitant treatment with drugs interacting with S-1. The following drugs
             are prohibited because there may be an interaction with S-1: phenytoin, potassium
             warfarin , flucytosine, cimetidine and folinic acid.

          -  Pregnant or lactation women, or women with known or suspected pregnancy and men who
             want let to pregnancy

          -  Ineligible for the study at the discretion of investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Capital Medical University Cancer Center</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2013</study_first_submitted>
  <study_first_submitted_qc>February 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2013</study_first_posted>
  <last_update_submitted>December 22, 2017</last_update_submitted>
  <last_update_submitted_qc>December 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Jun Ren MD, PhD</investigator_full_name>
    <investigator_title>Director,Capital Medical University (CMU)Cancer Center</investigator_title>
  </responsible_party>
  <keyword>Gastric cancer</keyword>
  <keyword>S-1</keyword>
  <keyword>DC-CIK</keyword>
  <keyword>T cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

